Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter ...

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Regeneron developed a higher dose (8 mg) of the drug, Eylea HD. Per Regeneron, on a combined basis, Eylea 2 mg and Eylea HD maintained their leadership position in the anti-VEGF category leader in ...

To counter the ongoing decline in Eylea sales, Regeneron developed a higher dose (8 mg) of the drug, Eylea HD. Per Regeneron, on a combined basis, Eylea 2 mg and Eylea HD maintained their leadership ...

The case arose from whistleblower claims brought by two former employees of Regeneron Pharmaceuticals, which manufactures and distributes Eylea (aflibercept 2 mg), one of the top-selling ...